

**REMARKS**

Favorable reconsideration of this application is requested in view of the above amendments and the following remarks. Claims 1-10 are pending. The feature of claim 2 is included in claim 1. The revisions to claim 4 are supported, for example, at paragraph [0023] on page 7. Method of treatment claims 7-10 are supported, for example at paragraph [0022] on page 7.

Claims 1-6 were rejected as unpatentable over Pinto in view of Kajimoto. Applicants respectfully traverse this rejection. The rejection relies on Pinto as disclosing the kotalanol extract from *Salacia reticulata*. The rejection contends that the difference between kotalanol and the present materials is merely the length of the carbon chain. However, the present materials in fact differ structurally from kotalanol in other ways as well, and particularly in the number of hydroxyl groups. Kotalanol has four hydroxyl groups in the chain attached to the SO<sub>4</sub>-bearing carbon, while the present materials have only three. The experimental results in the present specification demonstrate the unexpected properties of the present compound. More specifically, preparation example 2 reports the extraction and isolation of salacinol, kotalanol and reticulanol from *Salacia reticulata*. See the bottom of page 8 to the middle of page 10 of the present specification. These materials were examined for  $\alpha$ -glucosidase inhibitory activity. See pages 10-13 of the present specification. It can be seen that the present materials showed activity that was much higher than salacinol, which could not have been expected in view of the fact that the present materials actually are more closely related to salacinol from the strictly structural viewpoint than is kotalanol. Nothing in either reference suggests that such high  $\alpha$ -glucosidase inhibitory activity would be maintained in a material that actually is closer in structure to salacinol. Therefore, the rejection should be withdrawn.

The objection to claims 2 and 3 is rendered moot by their cancellation. Applicants are not conceding the correctness of the objection. Applicants submit that the revision to claim 4 obviates any potential objections relative to claims 5 and 6.


Applicants note that the foreign priority application for this case was addressed properly in the international stage, as acknowledged in the Form PCT/IB/304, a copy of which was submitted with the present national stage request papers. Therefore, no further action is needed to perfect the claim for priority, and Applicants request that the claim for priority be acknowledged in the next action.

In view of the above, Applicants request reconsideration of the application in the form of a Notice of Allowance.

Respectfully submitted,

HAMRE, SCHUMANN,  
MUELLER & LARSON, P.C.  
P.O. Box 2902  
Minneapolis, MN 55402-0902  
Phone: 612-455-3800

Date: December 10, 2007

By   
Name: Douglas P. Mueller  
Reg. No. 30,300  
Customer No. 52835